MRK - Coherus cancer drug undercuts Merck's Keytruda
2023-11-28 13:35:38 ET
More on Coherus BioSciences
- Coherus BioSciences Is A Buy On The Dip After Toripalimib Approval
- Coherus: The Surface Acquisition Is A Distraction
- Coherus BioSciences, Inc. (CHRS) Q3 2023 Earnings Call Transcript
- Coherus stock rises as Baird initiates coverage on multiple tailwinds
- Biggest stock movers today: BioMarin, Alteryx, Tripadvisor and more
For further details see:
Coherus cancer drug undercuts Merck's Keytruda